MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
Evoke Pharma EV/EBITDA Ratio 2011-2026 | EVOK
Annual EV/EBITDA Ratio Evoke Pharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -27.4 | -4.95 | -3.76 | -4.91 | -3.23 | -1.58 | -1.41 | -2.23 | -1.17 | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.17 | -27.4 | -5.62 |
EV/EBITDA Ratio of other stocks in the Drug manufacturers industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
4.15 | - | - | $ 142 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
0.353 | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-18.4 | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
-4.28 | $ 1.26 | -1.94 % | $ 136 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
-2.97 | - | 7.5 % | $ 6.35 M | USA |
 |
Cronos Group
CRON
|
-14.5 | $ 2.67 | 0.57 % | $ 1.42 B | Canada |
 |
Agile Therapeutics
AGRX
|
-18.5 | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
22.8 | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
1.47 | - | - | $ 50.1 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-0.0195 | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-1.44 | - | 2.45 % | $ 38.1 M | Canada |
 |
Eagle Pharmaceuticals
EGRX
|
160 | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-1.77 | - | - | $ 28.9 M |  Irlanda |
 |
Emergent BioSolutions
EBS
|
7.77 | $ 13.18 | -1.35 % | $ 675 M | USA |
 |
Athenex
ATNX
|
-1.1 | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-6.92 | $ 21.49 | 0.05 % | $ 2.04 B |  France |
 |
Evolus
EOLS
|
-9.74 | $ 5.5 | -4.12 % | $ 341 M | USA |
 |
Harrow Health
HROW
|
72.8 | $ 49.05 | -3.9 % | $ 1.6 B | USA |
 |
China Pharma Holdings
CPHI
|
51.8 | $ 1.31 | -3.32 % | $ 22.9 M |  China |
 |
Jupiter Wellness
JUPW
|
-50.5 | - | - | $ 33.6 M | USA |
 |
OrganiGram Holdings
OGI
|
-2.79 | $ 1.72 | -0.41 % | $ 402 M | Canada |
 |
Organogenesis Holdings
ORGO
|
15.8 | $ 4.18 | -0.83 % | $ 550 M | USA |
 |
Bausch Health Companies
BHC
|
18.6 | $ 7.79 | 0.13 % | $ 2.84 B | Canada |
 |
Lannett Company
LCI
|
-3.47 | - | 1.15 % | $ 7.11 M | USA |
 |
Sundial Growers
SNDL
|
-1.27 | $ 1.64 | 0.01 % | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
-4.16 | $ 3.77 | -0.28 % | $ 4.68 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-19.4 | $ 4.77 | -1.24 % | $ 67.1 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
0.202 | - | - | $ 193 M | Canada |
 |
Tilray
TLRY
|
-46 | $ 9.42 | 3.14 % | $ 5.82 B | Canada |
 |
Aurora Cannabis
ACB
|
-2.99 | $ 4.3 | 0.59 % | $ 86.3 M | Canada |
 |
Veru
VERU
|
31.2 | $ 2.39 | 3.46 % | $ 322 M | USA |
 |
Pacira BioSciences
PCRX
|
29.6 | $ 22.6 | -13.16 % | $ 1.05 B | USA |
 |
PetIQ
PETQ
|
9.82 | - | 1.64 % | $ 400 M | USA |
 |
cbdMD
YCBD
|
-2.7 | $ 1.04 | -3.7 % | $ 4.49 M | USA |
 |
Perrigo Company plc
PRGO
|
11.2 | $ 14.85 | 0.99 % | $ 2.04 B | USA |
 |
ProPhase Labs
PRPH
|
9.86 | - | - | $ 5.07 M | USA |
 |
Recro Pharma
REPH
|
13.4 | - | -4.76 % | $ 65.3 M | USA |
 |
Radius Health
RDUS
|
-13.2 | - | - | $ 1.42 B | USA |
 |
Rockwell Medical
RMTI
|
-13.7 | $ 0.96 | -2.11 % | $ 22.4 M | USA |
 |
Relmada Therapeutics
RLMD
|
-2.91 | $ 4.41 | -0.45 % | $ 133 M | USA |
 |
OptiNose
OPTN
|
-2.04 | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
7.11 | $ 9.25 | -0.64 % | $ 657 M | USA |
 |
PLx Pharma
PLXP
|
-1.81 | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
-0.17 | $ 5.37 | 1.13 % | $ 219 M | USA |
 |
SCYNEXIS
SCYX
|
-1.32 | $ 0.66 | -0.66 % | $ 31.6 M | USA |
 |
Tricida
TCDA
|
-3.32 | - | - | $ 3.25 M | USA |
 |
TherapeuticsMD
TXMD
|
-45.5 | $ 2.03 | -1.46 % | $ 21.2 M | USA |
 |
Viatris
VTRS
|
10.5 | $ 12.66 | 0.46 % | $ 15.3 B | USA |
 |
Zomedica Corp.
ZOM
|
8.79 | - | -0.21 % | $ 98 M | USA |